First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.
dividend - The company attracts income-focused investors seeking stable cash flows from defensive healthcare exposure.
Rising rates create moderate headwinds through higher financing costs on the company's debt (Debt/Equity of 1.87) and valuation multiple…
Watch on earnings: Organic revenue growth rates by segment (ostomy, continence, wound care) to assess market share trends, EBIT margin progression and impact of raw material cost inflation (polymer resins, adhesives), Free cash flow conversion rate and dividend payout sustainability given 34% FCF yield.
One Sentence Summary:
Coloplast A/S: the story is balanced — organic revenue growth rates in core markets (target: mid-single digits), particularly ostomy care volume trends in europe and north america.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.